7 patents currently held
28 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2036. from the record
Of the 28 now held by other companies, 10 name Primus Pharmaceuticals Inc. as their current owner, and 18 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2036
Next term end
7
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2038 · High confidence
Also notable
Ends Aug 2038 · High confidence
Also notable
Ends Jan 2036 · Low confidence
Stable Liquid Pharmaceutical Composition
US 11,639,391
Granted 2023. Computed term ends 2038.
Solid State Forms of Lenvatinib Mesylate
US 11,084,791
The earliest of the three still in force, granted 2021 and renewed since. Its term ends first, in 2038.
Pharmaceutical Composition for Treating Migraine
US 12,673,040
Granted 2026. Too new for citation comparison; protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Jun 2030 · Low confidence
The most cited patent in this portfolio, cited by 13 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
now held by Tonix Medicines, Inc.
Also notable
Ends Aug 2030 · High confidence
The largest patent family in this portfolio, 11 related applications, renewed at every maintenance window due so far. Protection runs to 2030.
now held by Primus Pharmaceuticals, Inc.
Also notable
Ends May 2036 · High confidence
The largest patent family in this portfolio, 7 related applications, renewed at every maintenance window due so far. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
now held by Scilex Holding Company
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Stable Fusion Protein Formulation | 1 in force | to Apr 2042 |
| Antibody Formulation | 1 in force | to Oct 2041 |
| Stable Formulations of Therapeutic Antibody | 1 in force | to Jul 2040 |
| Stable Antibody Formulation | 1 in force | to Jan 2040 |
| Solid State Forms of Lenvatinib Mesylate | 1 in force | to Aug 2038 |
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,673,040 | Pharmaceutical Composition for Treating Migraine held by Tonix Medicines, Inc. In force · Low confidence | In force | Low confidence | |
| US 11,639,391 | Stable Liquid Pharmaceutical Composition In force · High confidence | In force | High confidence | |
| US 11,084,791 | Solid State Forms of Lenvatinib Mesylate In force · High confidence | In force | High confidence | |
| US 12,024,561 | Stable Antibody Formulation In force · High confidence | In force | High confidence | |
| US 12,433,947 | Stable Formulations of Therapeutic Antibody In force · High confidence | In force | High confidence | |
| US 12,030,948 | Antibody Formulation In force · High confidence | In force | High confidence | |
| US 12,428,464 | Stable Fusion Protein Formulation In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 28 patents in force now held by others · 87 patents ended · 22 applications pending · 221 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.